
Professor
Pediatrics
+1 415 476-3831
Michelle Hermiston, MD, PhD focuses on elucidating the impact of immune dysregulation on hematologic disease and translating these findings into clinical use.
Publications
Perspectives on the current diagnostic and treatment paradigms in secondary hemophagocytic lymphohistiocytosis (HLH).
Orphanet journal of rare diseases
Multidisciplinary approach to treating complex immune dysregulation disorders: an adaptive model for institutional implementation.
Frontiers in immunology
The outcomes of pediatric extracranial malignant germ cell tumors: A decade of experience from a single institution in Southern Vietnam.
Current problems in cancer
A Phase 1 Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) in Children, Adolescents and Young Adults with High-Risk T-Cell Acut
Transplantation and cellular therapy
Fludarabine Pharmacokinetic-Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Mismatched Allogeneic Hematopoietic Cell Transplantation.
Transplantation and cellular therapy
High Exposure of Intravenous Alemtuzumab Is Associated with Increased Risk of Double-Stranded DNA Viral Infections in Patients with Non-Malignant Disease Undergoing Allogeneic HCT.
Transplantation and cellular therapy
Liberalizing Requirements for Hospital Proximity Post-CD19 CAR for Children with Low Burden B-ALL at Infusion.
Transplantation and cellular therapy
Younger Children Have Increased Mixed Myeloid Chimerism with Busulfan-Based Conditioning for Hematopoietic Cell Transplantation of Non-Malignant Disease.
Transplantation and cellular therapy
Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies.
Pediatric blood & cancer
Emapalumab Use in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: the REAL-HLH Study.
Arthritis & rheumatology (Hoboken, N.J.)
PP114 Topic: AS13–Hematology/Oncology/Stem Cell Transplant/Immunology: MORTALITY IN CHILDREN WITH HEMOPHAGOCYTIC LYMPHOHISTIOCTYOSIS IN LOW-, LOW-MIDDLE-AND UPPER MIDDLE-INCOME COUNTRIES: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Pediatric Critical Care Medicine
Cyclophosphamide and thiotepa increases risk of transplant-associated thrombotic microangiopathy.
Transplantation and cellular therapy
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.
Blood advances
Diagnosing and Grading of Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplant of Children, Adolescent and Young Adults treated in a Pediatric Institution with Pediatric Protocols.
Transplantation and cellular therapy
ANHL1522: Durable Immunity to EBV post Rituximab and Third Party LMP-specific T-cells: A Children's Oncology Group Study.
Blood advances
A Roadmap to Establishing Global Oncology as a Priority Initiative within a National Cancer Institute-Designated Cancer Center.
Journal of the National Cancer Institute
Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.
The oncologist
Real World Outcomes for AYA Patients with Relapsed/Refractory B-Cell ALL Receiving CD19-Directed CAR T-Cell Therapy.
Transplantation and cellular therapy
Risk Factors for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia.
Transplantation and cellular therapy
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies.
Journal for immunotherapy of cancer
Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patients.
Cancer reports (Hoboken, N.J.)
Mediport use as an acceptable standard for CAR T cell infusion.
Frontiers in immunology
Hemophagocytic lymphohistiocytosis and clonally related T-cell malignancies in a pediatric patient.
Pediatric blood & cancer
Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma.
Pediatric blood & cancer
HLH-like toxicities predict poor survival following use of tisagenlecleucel in children and young adults with B-ALL.
Blood advances
How I approach B-lymphoblastic lymphoma in children.
Pediatric blood & cancer
Three-year results from phase 1 of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.
Haematologica
Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium.
Blood advances
Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults.
Best practice & research. Clinical haematology
172 Diagnosing and Grading of SOS: Which Criteria Are Best?.
Transplantation and cellular therapy
345 Prophylactic Tocilizumab Decreases Incidence of Acute Graft-Versus-Host Disease Following Alpha/Beta T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Transplantation and cellular therapy
Allowing Relationships to Unfold: Consult Reason and Topics Discussed in Initial and Subsequent Palliative Care Visits Among Children Who Died From Relapsed/Refractory Cancer.
Journal of pediatric hematology/oncology nursing
Pre-clerkship Teaching and Learning in the Virtual Learning Environment: Lessons Learned and Future Directions.
Medical science educator
010 CD72 NANOBODY CAR-T CELLS HAVE POTENT ANTITUMOR EFFICACY IN B CELL MALIGNANCIES.
Leukemia research
049 A TARGETED GENE EXPRESSION CLASSIFIER IDENTIFIES PEDIATRIC T-ALL PATIENTS AT HIGH RISK FOR END INDUCTION MINIMAL RESIDUAL DISEASE POSITIVITY.
Leukemia research
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Anatomy of a Consult: How a Multidisciplinary Pediatric Stem Cell Transplant Team Considers Specialty Palliative Care Consultation (GP722).
Journal of Pain and Symptom Management
Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
British journal of haematology
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
Blood advances
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
American journal of hematology
A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients.
Pediatric blood & cancer
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report.
Blood advances
Decreased IL-10 accelerates B-cell leukemia/lymphoma in a mouse model of pediatric lymphoid leukemia.
Blood advances
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Digenic Inheritance: Evidence and Gaps in Hemophagocytic Lymphohistiocytosis.
Frontiers in immunology
Perceptions of specialty palliative care and its role in pediatric stem cell transplant: A multidisciplinary qualitative study.
Pediatric blood & cancer
IFN-? signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS.
Blood advances
ALL-026: Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study.
Clinical Lymphoma Myeloma & Leukemia
Poster: ALL-026: Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study.
Clinical Lymphoma Myeloma & Leukemia
Subcutaneous panniculitis-like T-cell lymphomas with homozygous inheritance of HAVCR2 mutations in Vietnamese pedigrees.
Pediatric blood & cancer
Concurrent Subcutaneous Panniculitis-like T-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia in 2 Pediatric Patients.
Journal of pediatric hematology/oncology
Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.
Journal of Clinical Oncology
Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes.
The Journal of clinical investigation
Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
Clinical cancer research : an official journal of the American Association for Cancer Research
The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemia.
Cancer drug resistance (Alhambra, Calif.)
Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO).
Pediatric blood & cancer
The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities.
Cancer drug resistance (Alhambra, Calif.)
Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.
Journal of Clinical Oncology
Lymphoblastic lymphoma in children and adolescents: review�of current challenges and future opportunities.
British journal of haematology
Age-Related Impaired Efficacy of Bone Marrow Cell Therapy for Myocardial Infarction Reflects a Decrease in B Lymphocytes.
Molecular therapy : the journal of the American Society of Gene Therapy
High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL.
SLAS discovery : advancing life sciences R & D
Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas.
Pediatric blood & cancer
Abstract 2642: Preclinical efficacy of daratumumab in acute lymphoblastic leukemia.
Clinical Research (Excluding Clinical Trials)
Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.
Proceedings of the National Academy of Sciences of the United States of America
Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.
British journal of haematology
MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.
Blood
Abstract 2608: Ibrutinib significantly improves survival in a human Burkitt lymphoma (BL) xenograft NSG mouse model: Ibrutinib may be a potential adjuvant agent in the treatment of BL.
Experimental and Molecular Therapeutics
Unbiased modifier screen reveals that signal strength determines the regulatory role murine TLR9 plays in autoantibody production.
Journal of immunology (Baltimore, Md. : 1950)
Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia.
British journal of haematology
The structural wedge domain of the receptor-like tyrosine phosphatase CD45 enforces B cell tolerance by regulating substrate specificity.
Journal of immunology (Baltimore, Md. : 1950)
Cellular and molecular mechanisms for lupus nephritis in a mouse model of systemic lupus erythematosus (159.4).
The Journal of Immunology
Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response.
Science translational medicine
An activating mutation in CD45 generates a novel murine model of hemophagocytic disorders in the context of a MHC Class 1 restricted TCR. (109.11).
The Journal of Immunology
Impact of TLR9 on hyper-responsive ITAM signaling in a mouse model of SLE (47.24).
The Journal of Immunology
Chapter 95 CD45.
Handbook of Cell Signaling
PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background.
Journal of immunology (Baltimore, Md. : 1950)
Requirement for CD45 in fine-tuning mast cell responses mediated by different ligand-receptor systems.
Cellular signalling
CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells.
Immunological reviews
Differential impact of the CD45 juxtamembrane wedge on central and peripheral T cell receptor responses.
Proceedings of the National Academy of Sciences of the United States of America
B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency.
The Journal of experimental medicine
Langerhans' Cell Histiocytosis.
Clinical Endocrine Oncology
Epstein-Barr virus-associated B cell lymphoproliferative disease in a child with neonatal-onset multisystem inflammatory disease.
Arthritis and rheumatism
Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production.
Proceedings of the National Academy of Sciences of the United States of America
Chapter 114 CD45.
Handbook of Cell Signaling
A practical approach to the evaluation of the anemic child.
Pediatric clinics of North America
Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases.
The Journal of clinical investigation
CD45: a critical regulator of signaling thresholds in immune cells.
Annual review of immunology
Forced expression of the tumor suppressor adenomatosis polyposis coli protein induces disordered cell migration in the intestinal epithelium.
Proceedings of the National Academy of Sciences of the United States of America
Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system.
Genes & development
Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin.
Science (New York, N.Y.)
Organization of the crypt-villus axis and evolution of its stem cell hierarchy during intestinal development.
The American journal of physiology
In vivo analysis of cadherin function in the mouse intestinal epithelium: essential roles in adhesion, maintenance of differentiation, and regulation of programmed cell death.
The Journal of cell biology
Differentiation and self-renewal in the mouse gastrointestinal epithelium.
Current opinion in cell biology
Chimeric-transgenic mice represent a powerful tool for studying how the proliferation and differentiation programs of intestinal epithelial cell lineages are regulated.
Proceedings of the National Academy of Sciences of the United States of America
Use of transgenic mice to characterize the multipotent intestinal stem cell and to analyze regulation of gene expression in various epithelial cell lineages as a function of their position along the cephalocaudal and crypt-to-villus (or crypt-to-surface e
Seminars in Cell and Developmental Biology
Simultaneous localization of six antigens in single sections of transgenic mouse intestine using a combination of light and fluorescence microscopy.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
Use of transgenic mice to infer the biological properties of small intestinal stem cells and to examine the lineage relationships of their descendants.
Proceedings of the National Academy of Sciences of the United States of America